Financial Data and Key Metrics Changes - In 2024, the company reported a revenue growth of approximately 40% year-over-year, with net product sales of $29.6 million compared to $21.3 million in 2023 [28][30] - For Q4 2024, net product sales were $7.9 million, reflecting a quarterly growth rate of approximately 13% [28] - The company managed to burn only approximately $0.6 million in cash for Q4 2024, demonstrating operational efficiency [34] Business Line Data and Key Metrics Changes - The pediatric segment continued to show growth, while the adolescent and young adult (AYA) segment emerged as a significant opportunity [38] - Selling and marketing expenses for Q4 2024 were $3.9 million, down from $4.6 million in Q3 2024, while full-year expenses increased to $18.4 million from $12.1 million in the previous year [29][30] Market Data and Key Metrics Changes - The U.S. AYA oncology landscape is estimated to have approximately 20,000 cisplatin chemotherapy patients treated annually, with significant market potential [11] - The product PEDMARK is gaining traction in major academic centers, which is critical for broader market acceptance [14] Company Strategy and Development Direction - The company is focused on expanding awareness of the unmet need for preventing cisplatin-induced ototoxicity and establishing PEDMARK as the standard of care [9][10] - The PEDMARK strategy will be utilized throughout 2025 to drive growth, with a focus on increasing adoption among oncologists and ensuring access for patients [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential for PEDMARK, particularly in the AYA segment, and anticipates significant growth in the second half of 2025 [41][42] - The company is actively engaging with stakeholders to support the inclusion of PEDMARK in key compendia, which is expected to enhance access and reimbursement pathways [17][18] Other Important Information - The company has launched PEDMARQSI in Germany and the U.K., with pricing set at £8277 in the U.K. and over €10,500 in Germany [20][21] - The company anticipates receiving a €10 million milestone upon obtaining final pricing approval in Germany [34] Q&A Session Summary Question: Did the pediatric business return to sequential growth in Q4, and what was the AYA contribution? - Management confirmed continued growth in the pediatric segment and highlighted the AYA segment as an incredible opportunity, though specific breakdowns were not provided [38] Question: What is the expected inflection in the AYA segment for 2025? - Management indicated significant opportunities in the AYA segment and expects accelerated growth in the second half of the year [41][42] Question: What progress has Norgine made in Europe regarding key centers of excellence? - Management noted that the product is now commercially available in the U.K. and Germany, with ongoing updates expected as more countries are approved [48][49] Question: What is the competitive landscape for PEDMARK in the U.S.? - Management acknowledged the presence of compounded products but emphasized the adoption of PEDMARK in major institutions, indicating progress despite competition [72] Question: Will clinical trials be run for potential label expansions? - Management indicated openness to discussions regarding label expansions and will provide updates as developments occur [75]

Core Viewpoint - Adherex Technologies Inc. reported a quarterly loss of $0.06 per share, significantly missing the Zacks Consensus Estimate of $0.56, marking an earnings surprise of -110.71% [1][2] Financial Performance - The company posted revenues of $7.93 million for the quarter ended December 2024, which was 73.17% below the Zacks Consensus Estimate and down from $9.74 million year-over-year [2] - Over the last four quarters, Adherex Technologies has not surpassed consensus EPS estimates and has only topped revenue estimates once [2] Stock Performance - Adherex Technologies shares have increased by approximately 8.9% since the beginning of the year, contrasting with a -1.9% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $8.7 million, and for the current fiscal year, it is -$0.15 on revenues of $57.11 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Adherex Technologies belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - Fennec Pharmaceuticals reported a significant increase in net product sales for PEDMARK, achieving $29.6 million for the full fiscal year 2024, which is a 40% increase year-over-year, and $7.9 million in Q4 2024, reflecting a 13% increase from the previous quarter [1][11][32] - The company has strengthened its leadership team and is focused on expanding the adoption of PEDMARK in academic institutions and new patient segments, particularly in the adolescent and young adult (AYA) market [3][32] - Fennec has successfully launched PEDMARQSI in the UK and Germany, enhancing global access to its product aimed at preventing cisplatin-induced hearing loss in pediatric patients [1][6][32] Financial Performance - For the fiscal year 2024, total revenue reached $47.5 million, with net product sales contributing $29.6 million, compared to $21.3 million in 2023 [11][12] - The company reported a cash position of $26.6 million as of December 31, 2024, with a notable increase in cash and cash equivalents of $13.4 million from the previous year [11][14] - Selling and marketing expenses increased to $18.4 million for FY 2024, up from $12.1 million in FY 2023, reflecting the company's efforts to expand outreach [11][12] Strategic Developments - Fennec completed an early repayment of $13 million of its convertible debt facility, optimizing its balance sheet and saving approximately $1.5 million in future interest payments [1][6] - The company is advancing its efforts to include PEDMARK in the NCCN Drug and Biologics Compendium, which is crucial for expanding access and reimbursement pathways [6][32] - A clinical trial in Japan (STS-J01) is fully enrolled, with results expected in the second half of 2025, potentially leading to registration of PEDMARK in Japan [1][6]

Core Viewpoint - Fennec Pharmaceuticals Inc. is set to release its full year and fourth quarter 2024 financial results on March 10, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing PEDMARK®, which aims to reduce the risk of platinum-induced ototoxicity in pediatric patients [3]. - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [3]. - The product has been granted Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [3]. Conference Call & Webcast Details - The conference call is scheduled for March 10, 2025, at 8:30 a.m. Eastern Time, with a live webcast available [2]. - Participants are advised to connect to the company's website at least 15 minutes prior to the call for any necessary software downloads [2]. - A replay of the conference call will be archived on the company's website for thirty days [2].

Group 1 - The stock of Adherex Technologies (FENC) is experiencing significant attention due to high implied volatility in the options market, particularly the Feb 21, 2025 $05.00 Call option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in the stock's price, potentially due to an upcoming event [2] - Adherex Technologies holds a Zacks Rank 3 (Hold) in the Medical-Biomedical and Genetics industry, which is in the top 30% of the Zacks Industry Rank, indicating a relatively stable outlook [3] Group 2 - Over the past 60 days, one analyst has raised the earnings estimate for the current quarter while another has lowered it, leading to a shift in the Zacks Consensus Estimate from a loss of 11 cents per share to a gain of 56 cents [3] - The high implied volatility may signal a developing trading opportunity, as options traders often seek to sell premium on options with high implied volatility, aiming to benefit from time decay [4]

Group 1 - Fennec Pharmaceuticals Inc. will participate in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, at the Sheraton New York Times Square Hotel [1][2] - The company focuses on the development and commercialization of PEDMARK, aimed at reducing the risk of platinum-induced ototoxicity in pediatric patients [2] - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [2] Group 2 - PEDMARK has Orphan Drug Exclusivity in the U.S., while PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [2]

Company Performance - Adherex Technologies Inc. reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, and compared to a loss of $0.07 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $6.97 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 23.61%, although this represents an increase from year-ago revenues of $6.52 million [2] - Over the last four quarters, Adherex Technologies has not surpassed consensus EPS estimates, and its shares have lost about 55.9% since the beginning of the year, contrasting with the S&P 500's gain of 24.3% [3][4] Earnings Outlook - The current consensus EPS estimate for the coming quarter is $0.12 on revenues of $16.53 million, and for the current fiscal year, it is $0.08 on revenues of $58.33 million [7] - The estimate revisions trend for Adherex Technologies is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Adherex Technologies belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of ranked industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations I ...

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Thursday, November ...

Adherex Technologies Inc. (FENC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they mi ...